Inspira™ technologies receives approval from sheba medical center to conduct clinical study of the hyla™ blood sensor

The clinical study is planned for q1-2023 to be performed on patients undergoing open-heart surgery at sheba medical center ra'anana, israel , feb. 13, 2023 /prnewswire/ -- inspira™ technologies oxy b.h.n. ltd. (nasdaq: iinn) (nasdaq: iinnw) (the "company" or "inspira technologies"), a company creating new acute respiratory care technologies, announced today that it has received approval by the ethics committee at sheba medical center in israel to conduct a clinical study of its hyla blood sensor in patients undergoing open-heart surgery.
IINN Ratings Summary
IINN Quant Ranking